Trial
NCT02689726
Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Genticel
Collaborators
PPD Development, LP
Condition
HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Intervention
GTL001+
Why stopped
Lack of efficacy in European Phase 2 study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-02